Antonio Giordano - Böcker

Liquid Biopsy: New Challenges in the era of Immunotherapy and Precision Oncology aims to describe links between cancer, precision oncology, and liquid biopsy, focusing on their participation to immunotherapy management. The book provides updated information on the main applications of liquid biopsy and immunotherapy as well as interesting aspects useful for planning basic and translational research activities. It helps readers understand the central aspects of precision medicine in oncology, including the use of new generation technologies for translational and diagnostic settings and the main clinical trials in this area that may be useful during their research.The book is a valuable source for cancer researchers, oncologists and other members of the medical and biomedical field who are interested in learning more about recent developments in liquid biopsy and its relationship with precision medicine and immunotherapy. Presents a "highlights section� in every chapter to help readers summarize the main aspects discussed Encompasses case reports to guide the reader on applying what they read in their clinical practice Includes several tables and figures specially created for the book to illustrate the meaning of what is expressed in the text

Cancer Epigenetics: Biomolecular Therapeutics in Human Cancer is the only resource to focus on biomolecular approaches to cancer therapy. Its presentation of the latest research in cancer biology reflects the interdisciplinary nature of the field and aims to facilitate collaboration between the basic, translational, and clinical sciences.

Leading clinicians and investigators review in a comprehensible and user-friendly style all the latest information about the molecular biology of cell cycle control and demonstrate its clinical relevance to understanding neoplastic diseases. Topics range from Cdk inhibitors and cell cycle regulators to the prognostic value of p27 and tumor suppressor genes as diagnostic tools. Actual case studies show how the new molecular understanding has produced such drugs as Flavopiridol and Sulindac. The book brings all the recent critical research findings to bear on clinical practice, and clearly shows their powerful impact on the diagnostics, prognostics, and therapeutics of cancer, AIDS, and cardiovascular disease.

Expert laboratorians detail emerging methodologies for studying the cell cycle, its kinases, and kinase inhibitors. The authors focus the issues of gene expression in vivo and in vitro, the analysis of cyclin-dependent kinase inhibitors, protein degradation mediated by the proteosome, the analysis of the transformed cell phenotype, and innovative techniques to detect apoptosis. Many of the protocols are new, such as electron microsocopy to detect apoptosis and proteosome-mediated degradation, whereas others study the interactions between protein protein, protein DNA, and protein RNA.

Complex physiopathological relationships have been proven to exist between two of the body’s most vital organs; the brain and the heart. In Cell Cycle Regulation and Differentiation in Cardiovascular and Neural Systems Antonio Giordano, Umberto Galderisi and a panel of the most respected authorities in their field offer an in-depth analysis of the differentiation process in two systems that have profound relationships with one another. The text looks at several aspects of the cardiovascular and nervous systems from a new point of view, describing the differences and similarities in their differentiation pathways with an emphasis on the role of cell cycle regulation and cell differentiation. Topics discussed include neurogenesis in the central nervous system, neural stem cells, and the basic-helix-loop-helix transcription factors in neural differentiation. Ground-breaking and authoritative, Cell Cycle Regulation and Differentiation in Cardiovascular and Neural Systems is a must have for all researchers in cardiovascular medicine and neuroscience and will prompt the scientific community to perceive cell cycle regulation and differentiation under a novel and more comprehensive light.

This text provides a comprehensive, state-of-the-art review of the application of image analysis focusing on the techniques which can be used in every biology and medical laboratory to automate procedures of cell analysis and to create statistics very useful for a comprehension of cell growth dynamics and the effects of drugs on them.

Molecular Pathology of Gynecologic Cancer focuses on putting successful molecular strategies into practice for the treatment of gynecologic cancer. The volume begins with an explication of the editors’ hypothesis that cancer is mainly a disease of the cell cycle, based on the deregulation of the physiological process of cell reproduction. The following eleven chapters focus on specific issues in gynecologic cancers, including: a proposed model of ovarian serous carcinogenesis, molecular markers for ovarian epithelial cancer, an overview of the pathology of endometrial cancer, molecular genetic aspects of endometrial carcinoma and cervical cancer, a natural history of Human Papilloma Virus (HPV) as it relates to cervical cancer, and hereditary issues in gynecologic cancers. The concluding chapter proposes and outlines a holistic approach to the treatment of female cancer patients. This new volume in Humana’s Current Clinical Oncology™ series will be necessary reading for clinicians and experimental researchers alike.

This text provides a comprehensive, state-of-the-art review of the application of image analysis focusing on the techniques which can be used in every biology and medical laboratory to automate procedures of cell analysis and to create statistics very useful for a comprehension of cell growth dynamics and the effects of drugs on them.

Molecular Pathology of Gynecologic Cancer focuses on putting successful molecular strategies into practice for the treatment of gynecologic cancer. The volume begins with an explication of the editors’ hypothesis that cancer is mainly a disease of the cell cycle, based on the deregulation of the physiological process of cell reproduction. The following eleven chapters focus on specific issues in gynecologic cancers, including: a proposed model of ovarian serous carcinogenesis, molecular markers for ovarian epithelial cancer, an overview of the pathology of endometrial cancer, molecular genetic aspects of endometrial carcinoma and cervical cancer, a natural history of Human Papilloma Virus (HPV) as it relates to cervical cancer, and hereditary issues in gynecologic cancers. The concluding chapter proposes and outlines a holistic approach to the treatment of female cancer patients. This new volume in Humana’s Current Clinical Oncology™ series will be necessary reading for clinicians and experimental researchers alike.

Complex physiopathological relationships have been proven to exist between two of the body’s most vital organs; the brain and the heart. In Cell Cycle Regulation and Differentiation in Cardiovascular and Neural Systems Antonio Giordano, Umberto Galderisi and a panel of the most respected authorities in their field offer an in-depth analysis of the differentiation process in two systems that have profound relationships with one another. The text looks at several aspects of the cardiovascular and nervous systems from a new point of view, describing the differences and similarities in their differentiation pathways with an emphasis on the role of cell cycle regulation and cell differentiation. Topics discussed include neurogenesis in the central nervous system, neural stem cells, and the basic-helix-loop-helix transcription factors in neural differentiation. Ground-breaking and authoritative, Cell Cycle Regulation and Differentiation in Cardiovascular and Neural Systems is a must have for all researchers in cardiovascular medicine and neuroscience and will prompt the scientific community to perceive cell cycle regulation and differentiation under a novel and more comprehensive light.

Breast Cancer is the most common tumor in women and the second leading cause of cancer deaths worldwide. Due to breakthroughs in gene profiling, the knowledge of the pathophysiology of the mammary gland had greatly increased over the last decade. In Breast Cancer in the Post Genomic Era, Antonio Giordano, Nicola Normanno, and a panel of international authorities in their field provide a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma.The book provides a comprehensive approach to breast cancer, describing the use of gene profiling techniques to distinguish specific features of individual carcinomas, as well as emerging novel therapeutic approaches to treatment. Additional chapters cover the use of transgenic mice to model human breast cancer and the role of the EGF-CFC family in mammary gland development and neoplasia. Breast Cancer in the Post Genomic-Era succeeds in looking at breast cancer pathogenesis, diagnosis, and treatment under a more comprehensive light, and is a valuable resource for any Radiation or Surgical Oncologist, Cancer Biologist or Pathologist.

Breast Cancer is the most common tumor in women and the second leading cause of cancer deaths worldwide. Due to breakthroughs in gene profiling, the knowledge of the pathophysiology of the mammary gland had greatly increased over the last decade. In Breast Cancer in the Post Genomic Era, Antonio Giordano, Nicola Normanno, and a panel of international authorities in their field provide a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma. The book provides a comprehensive approach to breast cancer, describing the use of gene profiling techniques to distinguish specific features of individual carcinomas, as well as emerging novel therapeutic approaches to treatment. Additional chapters cover the use of transgenic mice to model human breast cancer and the role of the EGF-CFC family in mammary gland development and neoplasia. Breast Cancer in the Post Genomic-Era succeeds in looking at breast cancer pathogenesis, diagnosis, and treatment under a more comprehensive light, and is a valuable resource for any Radiation or Surgical Oncologist, Cancer Biologist or Pathologist.

Leading clinicians and investigators review in a comprehensible and user-friendly style all the latest information about the molecular biology of cell cycle control and demonstrate its clinical relevance to understanding neoplastic diseases. Topics range from Cdk inhibitors and cell cycle regulators to the prognostic value of p27 and tumor suppressor genes as diagnostic tools. Actual case studies show how the new molecular understanding has produced such drugs as Flavopiridol and Sulindac. The book brings all the recent critical research findings to bear on clinical practice, and clearly shows their powerful impact on the diagnostics, prognostics, and therapeutics of cancer, AIDS, and cardiovascular disease.

Expert laboratorians detail emerging methodologies for studying the cell cycle, its kinases, and kinase inhibitors. The authors focus the issues of gene expression in vivo and in vitro, the analysis of cyclin-dependent kinase inhibitors, protein degradation mediated by the proteosome, the analysis of the transformed cell phenotype, and innovative techniques to detect apoptosis. Many of the protocols are new, such as electron microsocopy to detect apoptosis and proteosome-mediated degradation, whereas others study the interactions between protein-protein, protein-DNA, and protein-RNA.

Gastric cancer is one of the most common and potentially lethal gastrointestinal malignancy, but it is now at the forefront of modern oncology due to new discoveries.  In recent years, the field of gastric cancer has been transformed by many notable developments in both the diagnostic area and the therapeutic strategies.The main aim of the text is to propose a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for oncologists, pathologists, surgeons and researchers with an interest in gastric cancer.  The first chapters will review the interplay between pathogens and especially H. pylori, inflammation, genomic instability, and tumorigenesis. Secondly, an exhaustive overview of the diagnosis of gastric cancer from a clinical/endoscopic and pathologic perspectives will be illustrated. Two specific chapters will deal with tissue and serum biomarkers with an important role in diagnosis as well as prognostic and predictive markers of response to specific therapy. A central section of the book will focus on treatment options available today for patients. Surgery is the cornerstone of treatment for gastric cancer; however, the prognosis of patients with locally advanced disease is still poor even after curative resection. Therefore, in order to improve the prognosis of patients, especially with advanced stage, a multimodal strategy is advisable and is thoroughly addressed in the appropriate section. With the advent of next-generation sequencing and new preclinical model technologies, the genomic landscape of gastric cancer  has been delineated and  molecular characterizations finalized to novel therapeutic targets of each molecular subtype have been identified.  These advances are making it feasible to integrate clinical and phenotype-based diagnostic and therapeutic methods and are described in a dedicated section.  The text will conclude with chaptersfocusing on the future direction of gastric cancer research in the precision medicine era: an in-depth analysis of non-coding RNAs and their role in gastric cancer, the impact of  immunomodulation/immunotherapy and the perspectives of nano-medicine will be finally proposed to the audience. A brief review of the existing literature addressing the above mentioned topics will be present in each chapter.  This text will serve as a useful resource for physicians and researchers dealing with, and interested in, this challenging malignancy.  It will provide a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts.  All chapters will be written by experts in their fields and will include the most up to date scientific and clinical information.

This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage  potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing,during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects.The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.

Tumors of the mediastinum are usually diagnosed in young patients, but they can develop at any age and form any tissue that exists in or passes through the chest cavity. The diagnosis and the accurate assessment of the mediastinum masses represents a challenge, given their clinical variability from asymptomatic to producing symptoms of cough, chest pain, and dyspnea. Mediastinal tumors encompass a wide range of various neoplasms. The localization of mediastinal masses is critical in the diagnosis: the anterior mediastinal masses are generally thymomas, teratomas, substernal thyroid/parathyroid tissue, or lymphomas; the middle mediastinum massess are typically pericardial and bronchogenic cysts; the posterior mediastinum  masses are often neurogenic tumors and esophageal cysts. The wide variety of different entities demonstrates a heterogeneous spectrum of clinical and pathologic features, suggesting that a uniform “standard” management of these patients is not appropriate.   In this context, the proposed book will provide a comprehensive review of the mediastinal tumors according to different sites of the diseases, including the masses of anterior, middle and posterior mediastinum. The handling of these tumors requires a multidisciplinary approach due to the complex anatomy of the mediastinum as well as the different clinical, radiographic, and prognostic features. This book has risen from the desire to provide to the specialists in the field an easy, updated and practical guidelines title to facilitate the clinical practice of mediastinic masses. This book will be a comprehensive guide to clinical best practices developed through the opinions of experts in the field.

In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies.

In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies.

This text properly considers the most recent and relevant advances in molecular RB of GB, taking into account the related topics of pathobiology, and underscores the most promising translational perspectives from the preclinical to the clinical domain. Section I (From Bedside to Bench) discusses conditions associated with RT resistance of GB and the consequent RB hints, technology improvements intended to overcome RT-resistance of GB, mathematical modeling of RB parameters from clinical studies, the present impact of molecular prognostic factors in therapy of GB, and RT tolerance of normal brain. Section II (Preclinical Research and Pathobiology Topics) presents the traditional and mechanistic/molecular approaches to RB of GB, genetic and epigenetic studies on GB, issues of cell-death pathways, stem-like cells, invasiveness, tumor microenvironment, hypoxia, mi-RNA manipulations, and nanoparticle technology. Section III (Translational Perspectives) presents RB issues related to molecular profiling and classification of GB as frames of reference for clinical studies, translational perspectives of gene therapy, evolving protocols based on pre-clinical data and large data-bases and ontologic models. Radiobiology of Glioblastoma: Recent Advances and Related Pathobiology will be of great value to pathologists, medical oncologists, radiation oncologists as well as basic researchers and clinical investigators.

Facilitating the collaboration between the basic, translational, and clinical sciences, this book provides an overview of the genetic and epigenetic mechanisms underlying the formation and progression of gynecological cancers. Gynecological Cancers: Genetic and Epigenetic Targets and Drug Development gathers all of the molecular and cellular aspects of gynecological cancer together within one volume, providing detailed and up-to-date information on the etiology, diagnosis, and treatment of gynecological cancers. Gynecological Cancers: Genetic and Epigenetic Targets and Drug Development ​also discusses the racial and ethnic disparities in the treatment of gynecological cancers through cost effective modalities like single visit screening and diagnosis, well women clinics, and mobile clinics. Written and edited by leaders in the field, this volume within the Current Clinical Oncology series is an indispensable resource for today’s practicing oncologist.

The book provide a unique and valuable resource on the clinical relevance of liquid biopsy as well as on the technical aspects of liquid biopsy analysis.

This text properly considers the most recent and relevant advances in molecular RB of GB, taking into account the related topics of pathobiology, and underscores the most promising translational perspectives from the preclinical to the clinical domain.

Facilitating the collaboration between the basic, translational, and clinical sciences, this book provides an overview of the genetic and epigenetic mechanisms underlying the formation and progression of gynecological cancers.

The book provide a unique and valuable resource on the clinical relevance of liquid biopsy as well as on the technical aspects of liquid biopsy analysis.

In this context, the proposed book will provide a comprehensive review of the mediastinal tumors according to different sites of the diseases, including the masses of anterior, middle and posterior mediastinum.